Abnormally-fucosylated haptoglobin as a cancer marker
Author Information
Author(s): S. Thompson, B.M.J. Cantwell, C. Cornell, G.A. Turner
Primary Institution: The Medical School, Newcastle upon Tyne, UK
Hypothesis
Is the level of abnormally-fucosylated haptoglobin (FHp) in the blood related to tumor burden in women with ovarian or breast cancer undergoing chemotherapy?
Conclusion
The study found that elevated levels of FHp in the blood are associated with increasing tumor burden but do not correlate with gross liver metastasis.
Supporting Evidence
- FHp levels were significantly associated with patient response to therapy.
- Patients with complete response had undetectable or weak FHp levels.
- There was no significant correlation between FHp levels and liver metastases.
Takeaway
This study shows that a special protein in the blood can help doctors understand how much cancer is in a person's body, but it doesn't help with liver cancer spread.
Methodology
Blood specimens were collected from women with ovarian and breast cancer, and FHp levels were measured using a fucose-binding lectin.
Limitations
The study did not assess the presence of micrometastases, which may affect FHp production.
Participant Demographics
21 women with ovarian cancer and 27 women with breast cancer, median age 60 years.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Want to read the original?
Access the complete publication on the publisher's website